Evidence-based adverse outcome pathway approach for the identification of BPA as en endocrine disruptor in relation to its effect on the estrous cycle. (5th November 2018)

• Record Type: Journal Article
• Authors: Viguié, Catherine; Mhaouty-Kodja, Sakina; Habert, René; Chevrier, Cécile; Michel, Cécile; Pasquier, Elodie
• Is Part Of: Molecular and cellular endocrinology. Volume 475(2018)
• Page Start: 10
• Page End: 28
• Publication Date: 2018-11-05
• Subjects: Bisphenol A -- Endocrine disruption -- Female reproduction -- Estrogen; ↑ increase -- ↓ decrease -- 2G 2-generation study -- 3G 3-generation study -- ANSES Agence Nationale de Sécurité Sanitaire de l'alimentation, de l'environnement et du travail, (French Agency for Food, Environmental and Occupational Health & Safety) -- AOP adverse outcome pathway -- ARC arcuate nucleus -- AVPV anteroventral periventricular nucleus -- BMP-15 bone morphogenic protein 15 -- BPA bisphenol A -- bw body weight -- CL corpora lutea -- CLARITY-BPA Consortium Linking Academic and Regulatory Insights on BPA Toxicity -- CREB cAMP response element-binding protein -- CYP45017a 17a-hydroxylase-17, 20-desmolase (also named CYP17A1) -- CYP450arom cytochrome P450 aromatase (also named CYP19A1) -- CYP450scc P450 cholesterol side chain cleavage enzyme (also named CYP11A1) -- DES diethylstilbestrol -- DHEA dehydroepiandrosterone -- DiE-1 diestrus-1 -- dpc days post conception -- E2 17-β estradiol -- EB estradiol benzoate -- ECHA European Chemical Agency -- ED endocrine disruptor -- EE2 ethinylestradiol -- ER estrogen receptor -- EU European Union -- F female -- FSH follicle stimulating hormone -- GATA4 a transcription factor characterized by its ability to bind to the DNA sequence "GATA" -- GD gestation day -- GDF-9 growth/differentiation factor 9 -- GnRH gonadotrophin-releasing hormone -- GPER G protein-coupled estrogen receptor -- HPG hypothalamic–pituitary–gonadal axis -- HSD3β 3β-hydroxysteroid dehydrogenase -- HSD17β 173β-hydroxysteroid dehydrogenase -- IGF-2 insulin-like growth factor 2 -- IVF in vitro fertilization -- KGN human cell line from ovarian granulosa cell tumor -- Kiss1R kisspeptin receptor -- LH luteinizing hormone -- LRH1 liver receptor homolog 1 -- M male -- MoA mode of action -- NTP US National Toxicology Program -- OVX ovariectomized -- PCNA proliferating cell nuclear antigen -- PCOS polycystic ovary syndrome -- PE proestrus -- PGF2α prostaglandin F2-alpha -- PII proximal promoter II -- PND postnatal day -- PPARγ Peroxisome Proliferator Activated Receptor gamma -- PPT propyl pyrazoletriol (ERα agonist) -- PR progesterone receptor -- PRL prolactin -- RAC Risk Assessment Committee -- REACH Registration, Evaluation, Authorisation and Restriction of Chemicals -- RP3V rostral periventricular area of the third ventricle -- RT-PCR reverse transcription polymerase chain reaction -- SD Sprague Dawley -- SF-1 steroidogenic factor 1 (transcription factor) -- SG-BPA BPA specific gravity -- StAR steroid acute regulatory protein -- SVHC substance of very high concern -- T testosterone -- WHO World Health Organization -- WOE Weight of Evidence; Endocrinology -- Periodicals; Molecular biology -- Periodicals; Cytology -- Periodicals; Endocrinology -- Periodicals; Hormones -- Periodicals; Endocrinologie -- Périodiques; Cytology; Endocrinology; Molecular biology; Periodicals; 573.4
• DOI: 10.1016/j.mce.2018.02.007
• Languages: English
• ISSNs: 0303-7207

Abstract

Abstract: Proper cyclicity is essential to reach successful optimal fertility. In rats and mice, BPA exposure is repeatedly and reliably reported to show an adverse effect on the estrous cycle after exposures at different life stages. In humans, a possible association between modifications of menstrual cycle characteristics (e.g. length of the cycle, duration of menstrual bleeding) and sub-fecundity or spontaneous abortion has been observed. Alterations of ovarian cyclicity can therefore be definitely considered as an adverse health outcome. As a prerequisite for the EU REACH regulation to identify a substance as an endocrine disruptor and a SVHC, 1 the proof has to be established that the substance can have deleterious health effects resulting from an endocrine mode of action. This review provides an overview of the currently available data allowing to conclude that the adverse effects of BPA exposure on ovarian cyclicity is mediated by an endocrine mode of action. Highlights: BPA alters ovarian steroidogenesis in adult females via aromatase reduction. BPA fetal exposure is associated to altered estrous cyclicity. BPA fetal exposure alters neuroendocrine functions critical for female reproduction.